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ABSTRACT 
 
Umbilical cord (UC) is a very promising source of mesenchymal stem cells (MSCs) for allogeneic use, as it can be 
collected easily without side effects to the donor. In this study, we developed a simple production protocol to get 
UC-MSCs using xeno-free material to provide safe MSCs for translational research in regenerative medicine. In 
this study, we used multiple harvest explant method to isolate the MSCs. The medium for isolation and propagation 
was 10% platelet concentrate (PC) containing alpha MEM. Confluent cultures were harvested, combined and 
counted. Primary cultures were expanded in T25 flasks (seeding around 5000/cm2) to passage-1 (P-1) and P-2, and 
the results of P-1 and P-2 cultures were counted.   From 5 cm of umbilical cord, we did explant culture in four 24 
well plates. The number of harvest per well ranges from 0-5 times i.e. no harvest= 6, once= 20, twice= 34, three 
times= 27, four times=8, and five times= 1 well(s), respectively. Therefore, we harvested a total of 206 times from 
the 96 wells, and got a total of 3,595,600 cells from the primary culture. If we use all of the cells from the primary 
culture for expansion, we will get a total of 47,809,462 cells in passage-1, a total of 1,022,607,122 cells in passage-
2. In conclusion, UC-MSCs can be isolated and expanded easily in 10% PC containing alpha MEM, and is suitable 
to fill the demand of allogeneic MSCs for patient use. 
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INTRODUCTION 
 
Production of safe stem cells, in particular mesenchymal stem cells as bio-pharmaceutics, is very important in 
regenerative medicine. Mesenchymal stem cells have immunosuppressant properties in vitro and in vivo, and low 
immunogenicity [1]. Moreover, a meta-analysis of MSC using clinical trials, where some of the clinical trials used 
unmatched allogeneic MSCs, showed no serious adverse effect [2]. Therefore, MSCs might be regarded safe for 
allogeneic use. However, production procedure that uses fetal bovine serum (FBS) may be harmful to patients as 
xenomaterial in FBS can be incorporated into the cells and difficult to be eliminated [3]. 
 
Umbilical cord (UC) is a very promising source of mesenchymal stem cells (MSCs) for allogeneic use, as it can be 
collected easily without side effects to the donor. Moreover, UC-MSCs can be expanded more compared to bone 
marrow or other adult tissue derived MSCs [4], and thus they are more readily available for allogeneic use.  
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Previous studies isolated MSCs from UC tissue using enzymatic processings [5, 6] or explant method that was 
harvested once [7, 8, 9]. We have developed a multiple harvest method, which can harvest the explant more than 
once. However, in the original multiple harvest study, we put three pieces of UC tissue in a well, and observed that 
the explants did not became confluent at the same time [10]. Therefore, in this study, we modified the method and 
developed a simple production protocol to get UC-MSCs using xeno-free material to provide safe MSCs for 
translational research in regenerative medicine. 
 
EXPERIMENTAL SECTION 
 
This descriptive in vitro study was conducted in Stem Cell Medical Technology Integrated Service Unit, Cipto 
Mangunkusumo Central Hospital - Faculty of Medicine Universitas Indonesia from April through July 2014. Ethical 
clearance for this study was obtained from Ethical Committee for medical research of the Faculty of Medicine 
Universitas Indonesia (no. No.665/UN2.F1/ETIK/2014). The sample was elected caesarean section derived full term 
UC, which was obtained after the mother signed an informed consent form. The UC was processed and isolation of 
MSCs was done by modification of multiple harvest explant method [10].  
 
Processing of UC 
In brief, 5 cm of UC was washed in 0.5% povidone iodine [Betadine] containing phosphate buffered saline pH 7.4 
(PBS [Sigma P3813]), followed by washing in PBS. The umbilical arteries and vein were discarded, and the UC 
tissue was minced into small pieces of 2-5 mm in complete medium to prevent drying. The complete medium was 
penicillin/ streptomycin (final concentration 100U/mL), amphotericin B (final concentration 2500ng/mL), 1% L-
Glutamine (Lonza 17-605C), and 10% platelet concentrate (PC [Indonesian Red Cross]) containing α minimum 
essential medium (αMEM) [GIBCO 12000-022 1]. Then one piece of UC (explant) was put in each well of 24 well 
plates (growth area 1.9 cm2 [Biolite]).  On each piece, one drop of complete medium was added to prevent drying, 
and the plates were incubated in 37oC under 5% CO2.  
 
Explant culture  
The explant culture was observed everyday. When necessary, one drop of complete medium was added, and when 
the explant attached to the bottom, 0.5 ml of complete medium was added. The medium was changed every 2-3 
days.  
 
Harvest and passage 
Confluent cultures were harvested using TrypLE Select [GIBCO 12563-011], combined and counted. Part of the 
results of primary cultures were expanded in T25 flasks (seeding around 5000/cm2), and the rest was cryopreserved. 
After harvest, the explants were recultured several times untill the explants were detached from the bottom.  
 
The results of passage-1 (P-1) cultures were combined, and counted. Further, part of the P-1 culture was cultured 
into passage-2 (P-2), and part of P-2 cultures was checked for their differentiation capacity, and the rest was 
cryopreserved.  
 
Characterization of the cells 
Cryopreserved P-1 derived P-2 cells were characterized for their surface markers (CD90,CD73 and CD34) by 
flowcytometry, and 10,000 total events were analyzed. Further, the cells were cheched for their differentiation 
capacity into chondrogenic lineage by prolonged culture [11], into adipogenic lineage by adipogenic induction 
medium (StemPro adipogenesis [GIBCO A10070-01]), and into osteogenic lineage by osteogenic induction medium 
(StemPro osteogenesis [GIBCO A10072-01]). 
 
Data collection and analysis 
Data collected were cell morphology, property, and characteristics in term of their surface markers and 
differentiation capacity. Further, number of harvest per well, number of seeding in P-1 and P-2, and number of 
harvested cells in P-0, P-1 and P-2 were noted. Cumulative harvest number, total seeded cell number in P-1 and P-2, 
and total harvested cell number in P-0, P-1 and P-2 were calculated. Further, putative total harvested cells in P-1 and 
P-2 were computed.  
 
RESULTS AND DISCUSSION 
 
From 5 cm of UC, we did explant culture in four 24 well plates (total number of wells= 96 wells). The number of 
harvest per well ranges from 0-5 times i.e. no harvest= 6, once= 20, twice= 34, three times= 27, four times=8, and 
five times= 1 well(s), respectively. Therefore, we harvested a total of 206 times from the 96 wells, and got a total of 
3,595,600 cells from the primary culture.  
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The cells in P-0, P-1, and P-2 were fibroblastic and plastic adherent. For passage-1, a total of 1,450,560 cells were 
expanded in twelve T25 flasks, and we got a total of 19,287,600 cells. For passage 2, a total of 871,280 cells were 
expanded in seven T25 flasks, and we got a total of 18,636,000 cells.  
 
If we use all of the cells from the primary culture result for expansion, we will get a total of 47,809,462 cells in P-1. 
Further, if we use all of the putative result of P-1 for expansion, we will get a total of 1,022,607,122 cells in P-2, 
which is equivalent to 20 doses of 50,000,000 cells for patients with 50 kg body weight.   
 
We have developed a simple production method of UC-MSC from 5 cm of UC using xeno-free media that gave 
enough P-2 cells for around 10 patients (100,000,000 cells per patient). Our method does not require collagenase 
and hyaluronidase, as in enzymatic method [6, 8]. Moreover, PC is prefered compared to other xeno-material-
containing imported supplements such as FBS or FBS derivate containing supplements.  Moreover, if we use 
outdated PC, we can get it free of charge. In our previous studies, we showed that PC contained various growth 
factors that are needed for cell growth [12], and outdated PC still contained the needed growth factors [13]. 
Therefore, using outdated PC as supplement can greatly reduce production cost. 
 
 
Figure 1. Flowcytometric analysis of P-2 UC-MSCs 
P-2= passage 2, UC= umbilical cord, MSCs= mesenchymal stem cells 
 
Flowcytometric analysis of P-2 cells showed that CD90, CD73, and CD34 were 92.87%, 67.63%, and 2.62%, 
respectively (Figure 1). Induction of passage-2 cells showed differentiation capacity into osteogenic, chondrogenic 
and adipogenic lineage (Figure 2). However, differentiation into adipogenic cells yielded preadipocytes that contain 
smaller lipid droplets compared to those developed in bone marrow derived MSCs. 
 
Flowcytometric analysis of P-2 cells showed that the surface markers nearly reach International Society for Cell 
Therapy (ISCT) consensus for mesenchymal stem cells, i.e. CD90 and CD73 ≥95%, and CD34 ≤2% [14], and 
further passage might increase CD90 and CD73, and decrease CD34 as was shown in our previous study [15], to 
meet the consensus criteria of mesenchymal stem cells. Moreover, the presence of CD34 may be preferable as it is 
found not only on hematopoetic stem cells, but supposed to be present on a proportion of  mesenchymal stem cells, 
and  progenitors for various types of cells, including, muscle satelite cells, epithelial and vascular endothelial 
progenitors [16-18].  
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Figure 2. Differentiation capacity of P-2 UC-MSCs 
P-2= passage 2, UC= umbilical cord, MSCs= mesenchymal stem cells 
 
Further, P-2 UC-MSC can differentiate into chondrgenic, osteogenic, and adipogenic lineage, though the lipid 
dropplets in the adipogenic cells were smaller than those in induced bone marrow derived mesenchymal stem cells. 
This  phenomenon was also observed in our previous study [15], and the study of  Wagner et al [19], and Kern et al 
[20] on UC blood MSCs, which showed minimal adipogenic differentiation. 
 
CONCLUSION 
 
UC-MSCs can be isolated and expanded easily in 10% PC containing alpha MEM, and is suitable to fill the demand 
of allogeneic MSCs for translational research in regenerative medicine. 
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